Promising new antibiotic targets potentially deadly gut infections

April 12, 2013

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have developed a promising new antibiotic to treat potentially deadly gastrointestinal infections without harming the beneficial probiotic bacteria that help prevent relapse.

The investigational drug, Amixicile, can take down even hyper- of drug-resistant Clostridium difficile – commonly called "C. diff" – which kills 14,000 Americans each year. It also shows efficacy against Cryptosporidium (protozoans that cause diarrhea) and in mouse models of infection and potentially against many other human pathogens, including Campylobacter jejuni.

"You have an enzyme found in all these bad-guy bacteria, and our drug gets all of them," U.Va. researcher Paul Hoffman said. "It's remarkable to have one drug that has this kind of spectrum."

Because of Amixicile's expansive reach, Hoffman called it a "superdrug." It is so widely effective, he explained, because it targets enzymes shared by the .

"Most of the bad pathogens have this enzyme, and the good guys don't," Hoffman said. "The is absolutely the same in every one of these [harmful] organisms, so the way the drug works is the same for all these organisms, even though their enzymes are slightly different."

Recently completed preclinical studies show Amixicile has excellent safety and bioavailability indicators and is a good candidate for clinical trials, Hoffman said.

Amixicile could prove to be an important weapon against Clostridium difficile, an infection that often follows and strikes more than 400,000 people in the United States each year.

Amixicile offers significant advantage over existing treatments in its ability to spare the that help prevent a recurrence of the infection. In addition, high doses of Amixicile caused no adverse effects in mice, the U.Va. researchers reported.

"It's a very, very low toxicity drug," Hoffman said. "Best of all, we have not seen any indication of drug resistance, perhaps due to its novel mechanism of action.

"It has about every metric you could want in an antibiotic."

Hoffman and his fellow U.Va. researchers – including the School of Medicine's Dr. Richard L. Guerrant, Dr. Cirle Warren and Timothy L. Macdonald, who also holds a post in the College of Arts & Sciences' chemistry department – continue to work with the National Institutes of Health, the sponsor of the preclinical studies. The next step is to test the safety and effectiveness of Amixicile in humans, to see if it is as effective and well-tolerated as it has been in mice.

Hoffman and his colleagues are working closely with the U.Va. Licensing & Ventures Group to identify industry partners to assist in bringing the drug to market, so it may ultimately benefit patients.

Related Stories

Hope for powerful new C diff. treatment

September 19, 2011

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly ...

C. diff scientists reveal potential target to fight infections

November 30, 2012

Researchers at Virginia Bioinformatics Institute at Virginia Tech have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.